Health Canada Quality Guidance

DRAFT GUIDANCE FOR INDUSTRY Quality (Chemistry and Manufacturing) Guidance: New Drug Submissions (NDSs) and Abbreviated
New Drug Submissions (ANDSs)
Published by authority of the Minister of Health
Draft date
2001/07/18
Health Products and Food Branch Guidance Document
Our mission is to help the people of Canada maintain and improve their health. Health Canada
Our mandate is to promote good nutrition and informed use of drugs, food, medical devices and natural health products, and to maximize the safety and efficacy of drugs, food, natural health products, medical devices, biologics and related biotechnology products in the Canadian marketplace and health system. Health Products and Food Branch
THERAPEUTIC PRODUCTS DIRECTORATE WEBSITE (TP-Web) LET YOUR COMPUTER DO THE SEARCHING! ... Need to know how to market a new drug in Canada? ... Want information on the drug regulatory process? ... Need to know what the newest drugs on the Canadian market are? ... Want direct access to forms and policies? ... Need to know the requirements for labelling drugs? All this and more is available on the Therapeutic Products Directorate Website at www.hc-sc.gc.ca/hpb-dgps/therapeut
Minister of Public Works and Government Services Canada <2001> Available in Canada through Health Canada - Publications Brooke Claxton Building, A.L. #0913A Tunney's Pasture Ottawa, Ontario K1A 0K9 Tel: (613) 954-5995 Fax: (613) 941-5366 galement disponible en franais sous le titre : Catalogue No. ISBN
Health Canada Draft Guidance for Industry
Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
FOREWORD
Guidance documents are meant to provide assistance to industry and health care professionals on how to comply with Health Canada policies, governing statutes and regulations. They also serve to provide review and compliance guidance to staff, thereby ensuring that Health Canadas mandate is implemented in a fair, consistent and effective manner. Guidance documents are administrative instruments not having force of law and, as such, allow for flexibility in approach. Alternate approaches to the principles and practices described in this document may be acceptable provided they are supported by adequate scientific justification. Alternate approaches should be discussed in advance with Health Canada to avoid the possible finding that applicable statutory or regulatory requirements have not been met. As a corollary to the above, it is equally important to note that Health Canada reserves the right to request information or material, or define conditions not specifically described in this guidance, in order to allow for the adequate assessment of the safety, efficacy or quality of a therapeutic product. Health Canada is committed to ensuring that such requests are justifiable and that decisions are clearly documented.
Draft date: 2001/07/18
21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67
TABLE OF CONTENTS
G GENERAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G 1 Purpose . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G 2 Scope . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G 3 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G 4 Notes on the Preparation of the Quality Summary and the Quality Module . . . . . . . . . . . 6 6 6 6 8
I INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 S DRUG SUBSTANCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 1 General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 1.1 Nomenclature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 1.2 Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 1.3 General Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 2 Manufacture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 2.1 Manufacturer(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 2.2 Description of Manufacturing Process and Process Controls . . . . . . . . . . . . . . . S 2.3 Control of Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 2.4 Controls of Critical Steps and Intermediates . . . . . . . . . . . . . . . . . . . . . . . . . . . S 2.5 Process Validation and/or Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 2.6 Manufacturing Process Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 3 Characterisation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 3.1 Elucidation of Structure and other Characteristics . . . . . . . . . . . . . . . . . . . . . . . S 3.2 Impurities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 4 Control of the Drug Substance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 4.1 Specification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 4.2 Analytical Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 4.3 Validation of Analytical Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 4.4 Batch Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 4.5 Justification of Specification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 5 Reference Standards or Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 6 Container Closure System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 7 Stability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 7.1 Stability Summary and Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S 7.2 Post-approval Stability Protocol and Stability Commitment . . . . . . . . . . . . . . . . . S 7.3 Stability Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P DRUG PRODUCT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 1 Description and Composition of the Drug Product . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 2 Pharmaceutical Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 2.1 Components of the Drug Product . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 2.1.1 Drug Substance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 2.1.2 Excipients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 2.2 Drug Product . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 2.2.1 Formulation Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 2.2.2 Overages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11 11 11 12 12 14 14 14 15 16 16 16 16 17 18 19 19 20 21 21 22 22 23 23 23 25 26 26 26 27 27 27 28 28 28 28
4
68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114
P 2.2.3 Physicochemical and Biological Properties . . . . . . . . . . . . . . . . . . . . P 2.3 Manufacturing Process Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 2.4 Container Closure System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 2.5 Microbiological Attributes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 2.6 Compatibility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 3 Manufacture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 3.1 Manufacturer(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 3.2 Batch Formula . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 3.3 Description of Manufacturing Process and Process Controls . . . . . . . . . . . . . . . P 3.4 Controls of Critical Steps and Intermediates . . . . . . . . . . . . . . . . . . . . . . . . . . . P 3.5 Process Validation and/or Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 4 Control of Excipients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 4.1 Specifications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 4.2 Analytical Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 4.3 Validation of Analytical Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 4.4 Justification of Specifications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 4.5 Excipients of Human or Animal Origin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 4.6 Novel Excipients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 5 Control of Drug Product . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 5.1 Specification(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 5.2 Analytical Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 5.3 Validation of Analytical Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 5.4 Batch Analyses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 5.5 Characterisation of Impurities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 5.6 Justification of Specification(s) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 6 Reference Standards or Materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 7 Container Closure System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 8 Stability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 8.1 Stability Summary and Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . P 8.2 Post-approval Stability Protocol and Stability Commitment . . . . . . . . . . . . . . . . P 8.3 Stability Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A 1 Facilities and Equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A 2 Adventitious Agents Safety Evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A 3 Novel Excipients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . R REGIONAL INFORMATION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . R 1 Production Documentation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . R 1.1 Executed Production Documents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . R 1.2 Master Production Documents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . R 2 Medical Devices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
28 29 29 29 30 30 30 31 31 32 32 33 33 34 34 34 35 35 35 35 37 37 38 38 39 40 40 41 42 43 44 44 44 44 44 45 45 45 45 46
M MISCELLANEOUS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 M 1 ICH Quality Guidance Documents (Chemical Entities) . . . . . . . . . . . . . . . . . . . . . . . . . . 47 M 2 Health Canada Quality Templates and Guidance Documents (Chemical Entities) . . . . . . . 48
115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161
G GENERAL G 1 Purpose This document is intended to provide guidance with regard to the Quality (i.e., Chemistry and Manufacturing) portion of New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs) containing drug substances and their corresponding products of synthetic or semi-synthetic origin, excluding Biotechnological/Biological (Schedule D) and Radiopharmaceutical (Schedule C) drugs, that are filed with Health Canada pursuant to Division C.08 of the Food and Drug Regulations. The purpose of the guidance document is to outline the Quality technical requirements and to assist submission sponsors in preparing the NDS and ANDS to ensure an effective and efficient review process. It can also be used as guidance on the requirements for related drug submissions (e.g., Supplemental NDSs, Supplemental ANDSs, Notifiable Changes, etc.). This document covers variety of NDSs and ANDSs and may not be applicable in its entirety for all cases. Alternate approaches to the principles and practices described in this document can be acceptable provided they are supported by adequate scientific justification. Sponsors are advised to discuss, in advance, alternate approaches in their drug submission to avoid rejection or withdrawal of the drug submission. G 2 Scope This guidance document applies to New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs) containing drug substances and their corresponding products of synthetic or semisynthetic origin, excluding Biotechnological/Biological (Schedule D) and Radiopharmaceutical (Schedule C) drugs, that are filed with Health Canada pursuant to Division C.08 of the Food and Drug Regulations. It can also be used as guidance on the requirements for related drug submissions (e.g., Supplemental NDSs, Supplemental ANDSs, Notifiable Changes, etc.). This guidance document occasionally makes reference to existing drugs. An existing drug is one that is not a new active substance but requires the filing of a New Drug Submission (NDS) or an Abbreviated New Drug Submission (ANDS) for which a Notice of Compliance has been previously issued pursuant to Division C.08 of the Food and Drug Regulations (e.g., generic products). This could also include submissions for new dosage forms, new strengths, etc.. G 3 Preamble With the finalization of the Common Technical Document (CTD), the International Conference on Harmonisation (ICH) has reached agreement upon a common format of applications for the registration of pharmaceuticals for human use. Within the CTD, is the Common Technical Document - Quality (CTD-Q) (Module 3) outlining the format for the Quality portion of applications for New Chemical Entities. Also as part of the CTD-Q exercise, the ICH process has produced a Quality Overall
Draft date: 2001/07/18 6
162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208
Summary (QOS) (Module 2) which is a summary that follows the scope and the outline of the Quality Module (Module 3). During the transitional period from July 2001 to the official CTD implementation date, drug submissions may be filed in the current Canadian, the Modified NDA, or the CTD format. When filing in a particular format, the applicable filing requirements for that format apply. This Quality (C&M) Guidance: NDSs and ANDSs follows the format recommended in ICHs CTD-Q. Where appropriate, the text from ICHs CTD-Q has been repeated in bold (including spelling convention) under each section, followed by further guidance to assist sponsors in the preparation of NDSs and ANDSs. This guidance document is an updated version of Health Canadas 1990 Chemistry and Manufacturing: New Drugs guideline. Quality Summary (Module 2 of the CTD or Part 2 of the NDS/ANDS): Subsection C.08.005.1 of the Food and Drug Regulations stipulates that new drug submissions (NDSs), abbreviated new drug submissions (ANDSs), supplemental new drug submissions (SNDSs), and abbreviated new drug submissions (SANDSs) must include a comprehensive summary of each human, animal and in vitro study referred to or contained in the submission or supplement. The intent of this requirement is to facilitate the evaluation of the extensive experimental data and hence contribute toward a more effective and timely processing of drug submissions. The Quality Summary is a comprehensive summary that follows the scope and the outline of the Quality Module (Module 3 of the CTD or Part 2 of the NDS/ANDS, whichever applies). The Quality Summary should not include information, data, or justification that was not already included in Quality Module or in other parts of the drug submission. Since 1995, sponsors of NDSs and ANDSs have been required to complete the Comprehensive Summary (Chemistry and Manufacturing) (CS(CM)). This document provided a summary of the Quality data submitted to Health Canada according to a prescribed format and hence contributed towards a more effective and timely processing of these drug submissions. The template has since been updated according to current Quality standards and terminology, as well as to reflect the developments on the international level. With the completion of the updated version of the template, Quality Overall Summary - Chemical Entities (New Drug Submissions and Abbreviated New Drug Submissions) (QOS-CE (NDS)), sponsors share responsibility the for the generation of the Quality evaluation report. The objectives of this document are two-fold: (a) expediting the review process by enabling Evaluators to more efficiently spend their time on drug submission assessment; and improving drug submission quality by way of a more thorough compilation and appraisal of data requirements by sponsors in conjunction with the completion of the QOS-CE (NDS).
(b)
The QOS-CE is an updated version of Health Canadas earlier Quality Summary templates (i.e., the Comprehensive Summary (Chemistry and Manufacturing) (CS(CM)) and the Quality Information Summary - Pharmaceuticals (QIS-P)).
209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254
While both ICHs Quality Overall Summary (QOS) and Health Canadas Quality Overall Summary Chemical Entities (New Drug Submissions and Abbreviated New Drug Submissions) (QOS-CE (NDS)) provide an overview of the information presented in the Quality Module (also referred to as the Quality portion of the drug submission), the latter is meant to precisely define the type and extent of information considered necessary to produce a Canadian Quality evaluation report, once supplemented by the Evaluators comments. Given their specific role within the Quality review process, sponsors of NDSs are encouraged to complete Health Canadas QOS-CE (NDS) to help ensure an effective and efficient review of drug submissions. Until such time that the CTD is a required format for ANDSs, and/or the eCTD is available for voluntary filing, sponsors of ANDSs are expected to use the QOS-CE (NDS). ICHs QOS and Health Canadas QOS-CE (NDS) are collectively referred to as the Quality Summary throughout the remainder of this document. Paper and electronic versions of the Quality Summary should be provided. The electronic version should be in a WordPerfect format. Quality Module (Module 3 of the CTD or Part 2 of the NDS/ANDS): This guidance document is intended to provide direction to sponsors as to what information should be included in the Quality Module (also referred to as the Quality portion of the drug submission). The following sections describe the elements of the Quality technical requirements. ICHs CTD should be consulted for other portions of the Quality Module (e.g., Table of Contents, Literature References). Certified Product Information Document - Chemical Entities (CPID-CE): The CPID-CE constitutes part of the Notice of Compliance (NOC) package. The CPID-CE is provides an accurate record of technical data in the drug submission at the time the NOC is issued, and thereafter serves as an official reference document during the course of post-approval inspections and post-approval change evaluations as performed by Health Canada. The CPID-CE template represents an condensed version of the Quality Summary template which represents the final, agreed upon key data from the drug submission review (e.g., minimal data on the manufacturer(s), drug substance/drug product specifications, stability conclusions, etc.). The CPID-CE template file is structured to permit the rapid assembly of the CPID-CE by copying requisite information from the corresponding portions of the Quality Summary filed with the original drug submission. It is understood that the numbering system of this document is not sequential. This was intentional to retain the same numbering as the parent Quality Overall Summary - Chemical Entities (QOS-CE) or Quality Overall Summary (QOS). For New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs), the CPID-CE should be provided upon request (i.e., typically when the review of the drug submission is near completion). For SNDSs, SANDSs, and Notifiable Changes (NCs), the CPID-CE should be submitted at the time of filing and provided in Module 1. It is acknowledged that when filing a Supplement or NC, the updated CPID-CE may include changes that did not require prior approval by Health Canada (e.g., as for Level 3 and 4 changes).
255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301
G 4 Notes on the Preparation of the Quality Summary and the Quality Module Sponsors are encouraged to devote the sufficient time necessary to prepare a clear, precise Quality Summary which is based on the detailed information that is submitted in the Quality Module. The filing of an inaccurate or an incomplete Quality Summary will result in greater expenditure of an Evaluators time in reviewing and summarizing data. In developing Health Canadas Quality Summary template, a balance was needed between providing sufficient instruction regarding the format and content of information sought and designing a document that could accommodate variability in the types of studies and products described in these drug submissions. With respect to the latter consideration, it is expected that the tables included in the QOS-CE (NDS) template may need to be modified (e.g., with data cells being split or joined, as necessary). Additional modification of table structure or the substitution of a narrative paragraph, can also be warranted in certain circumstances in order to best summarize the data. All titles/parameters listed in the default tables should nonetheless be retained or addressed, regardless of their perceived relevance, unless the subject matter of the entire table does not apply to the drug submission in question. For NDSs and ANDSs, if portions of the Quality Summary are clearly not relevant due to the nature of the drug substance or drug product, this should be indicated by the designation Not Applicable (e.g., under the heading of section P 4.5 if there are not any excipients of human or animal origin used in the manufacture of the drug product). Any portions that are Not applicable should not be deleted and should be accompanied by an explanatory note describing the reasons for the inapplicability. When the information in a section has been submitted in a prior drug submission in its entirety, without changes, the relevant section should be deleted and so noted under the Introduction, along with the name of the drug product, sponsor's name, date of the Notice of Compliance, and file number and submission control number of the cross-referenced submission. As in a SNDS, SANDS, or Notifiable Change (NC), those sections of the Quality Summary and the Quality Module affected by the proposed change should be submitted. Those sections not affected by the change can be deleted. As an example, Section S Drug Substance, should not be included in a Supplement for an additional strength when there is not any change proposed to the information of the drug substance as described in the approved, cross-referenced submission. The above practice should not be followed with respect to cross-referenced Drug Master Files (DMFs). DMFs should be identified in the appropriate sections (e.g., S 2.1, P 3.1). The sections of the Quality Summary should not be deleted. It is the sponsor's responsibility to submit the relevant non-proprietary information provided by the DMF Holder (e.g., from the Open DMF), obtained in the public domain, and/or developed by the sponsor. For DMF requirements, consult Health Canadas guidance document Product Master Files (soon to be renamed Drug Master Files). When the sponsor summarizes data obtained from the DMF Holder or the scientific literature, the source of reproduced information should be specified. The following information is intended to provide assistance to sponsors in preparing the Quality Summary and the Quality Module: (a) Reference to applicable Quality guidance documents are identified under the various sections.
9
302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348
Those developed by ICH are identified by their code name only (e.g., Q1A). Also provided, as an appendix to this document, is a comprehensive list of applicable Quality guidance documents. During the preparation of the drug submission, these Quality guidance documents should also be consulted as their content has not been repeated here. (b) Abbreviations should not be used in the Quality Summary unless initially defined and consistently used (e.g., N/A = Not applicable), or unless they represent well-established scientific abbreviations (e.g., HPLC, UV, etc.). For old drug substances in new drug products, submit sections S 2.1 Manufacturer(s), S 4.1 Specifications, S 4.4 Batch Analyses, S 6 Container Closure System, and S 7.1 Stability Summary and Conclusions, and any other pertinent components (e.g., particle size distribution); delete all the other non-applicable sections of the Drug Substance (S) portion. This guidance document makes reference to Schedule B compendial monographs, these are those compendial monographs that are recognized as official according to Schedule B to the Food and Drugs Act (e.g., USP, Ph.Eur., BP, etc.). The Quality information associated with any or all of the following scenarios may be submitted under one complete drug submission in the CTD format: For a drug product containing more than one drug substance (e.g., substance X, substance Y), the entire Drug Substance (S) section for one drug substance should be followed by the entire S section for the next drug substance, then followed by a single Drug Product (P) section. The name of the drug substance should be included in the headings of all applicable sections and subsections, to clearly distinguish the information for each drug substance. For a drug substance and/or drug product which is manufactured by more than one manufacturer (e.g. Manufacturer A and Manufacturer B, both manufacture the drug product using different equipment and separate facilities) and where there are differences in the Quality information associated with each manufacturer, the name of the manufacturer should be included in the heading of any affected sections and subsections, to clearly distinguish the drug substance and/or drug product information for each manufacturer. The numbering of the sections and subsections in this case should still be sequential. (e.g., P 3.3 Description of Manufacturing Process and Process Controls [Manufacturer A]; P 3.3 Description of Manufacturing Process and Process Controls [Manufacturer B]). NOTE the exceptions: Under S.2.1 Manufacturer(s) and P 3.1 Manufacturer(s), multiple manufacturers should be listed without the need for any unique identifiers. For a drug product with more than one dosage form (e.g., tablets, oral solution), the entire Drug Product (P) section for one dosage form should be followed by the entire P section for the next dosage form. The name of the dosage form should be included in the headings of all applicable sections and subsections, to clearly distinguish the quality information for each dosage form. For a drug product with more than one strength (e.g.. 10, 50, and 100 mg tablets), identification of the strength should be included in the heading of any affected sections, subsections, and/or
Draft date: 2001/07/18 10
(c)
(d)
(e)
349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371
presentation of the information, to clearly distinguish the information for each strength. The numbering of the sections and subsections in this case should still be sequential. (f) When filing a response to a deficiency request from Health Canada (e.g., Request for Clarification (Clarifax), Notice of Non-compliance (NON), Notice of Deficiency (NOD)), sponsors should use the applicable sections of the Quality Summary to summarize new or updated data (e.g., specifications, analytical procedures, stability results, etc.). A refiled/updated Quality Summary should not be submitted. However, in the case of an NOD or an extensive NON where the magnitude of deficiency comments warrants the filing of replacement volumes, a refiled/updated Quality Summary can be necessary.
(g)
In order to facilitate the processing and evaluation of responses to deficiency requests from Health Canada, an electronic version of the consolidated deficiency comments and responses pertaining to the Quality issues should be provided in a question and answer format in a WordPerfect format.
Reference Guidances: M4Q (i.e., CTD-Q) Preparation of a Drug Submission in CTD Format (for CTD-based submissions) Preparation of Human New Drug Submissions (for NDS-based submissions) Modified FDA Format Drug Submissions for Products in Human Use
11
372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417
I INTRODUCTION The introduction should include proprietary name, non-proprietary name or common name of the drug substance, company name, dosage form(s), strength(s), route of administration, and proposed indication(s). Sponsors may provide a contact persons name, phone number, fax number, and e-mail address for ease of communication. S DRUG SUBSTANCE Some of the information included under the S Drug Substance section may not be available to the sponsor for the New Drug Submission or Abbreviated New Drug Submission. If such is the case, the supplier of the drug substance can file a Drug Master File directly with Health Canada. The supplier would then be considered the DMF Holder. This DMF will be held in strict confidence and will be used in support of the drug submission only upon receipt of written authorization from the supplier/DMF Holder of the drug substance (i.e., via a letter of access). The sponsor should be able to provide most of the information on the drug substance, except possibly the proprietary information found in sections S 2.2, S 2.3, S 2.4 and S 2.6 (see below). It is the responsibility of the sponsor to obtain all other information from the supplier of the drug substance and include this in the drug submission. The information from the Open DMF should be provided in the drug submission and summarized in the Quality Summary. Regardless of the information provided by the supplier of the drug substance, the manufacturer of the dosage form is responsible for ensuring that acceptable specifications and properly validated analytical procedures for the drug substance are developed by the manufacturers facilities and for providing the results of batch analyses performed at the manufacturer's facilities. For further information on the requirements for Drug Master Files, see Health Canadas guidance document Product Master Files (soon to be renamed Drug Master Files). S 1 General Information S 1.1 Nomenclature Information on the nomenclature of the drug substance should be provided. For example: (a) (b) (c) Recommended International Non-proprietary Name (INN); Compendial name, if relevant; Chemical name(s);
12
418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464
(d) (e)
Company or laboratory code; Other non-proprietary name(s) (e.g., national name, United States Adopted Name (USAN), British Approved Name (BAN)); and Chemical Abstracts Service (CAS) registry number.
(f)
The listed chemical names should be consistent with those appearing in scientific literature and those appearing on the product labelling (e.g., Product Monograph). Where several names exist, indicate the preferred name. Where a chemical moiety is formed in-situ (e.g., by chemical reaction), both the starting and chemical moiety should be described. S 1.2 Structure The structural formula, including relative and absolute stereochemistry, the molecular formula, and the relative molecular mass should be provided. This information should be consistent with that provided in section S 1.1. For drug substances existing as salts, the molecular mass of the free base should also be provided. S 1.3 General Properties A list should be provided of physicochemical and other relevant properties of the drug substance. This information can be used in developing the specifications, in formulating dosage forms, and in the testing for release and stability purposes. Give the physical and chemical properties of the drug substance such as the physical description, solubilities in common solvents (e.g., water, alcohols, chloroform, acetone, etc.), quantitative aqueous pH solubility profile (e.g., pH 1 to 8, dose/solubility volume), polymorphism, particle size distribution, pH and pKa values, UV absorption maxima and molar absorptivity, melting point, refractive index (for a liquid), hygroscopicity, partition coefficient, etc.. This list is by no means exhaustive, but provides an indication as to the type of information that could be included. Some of the more important properties to be considered for all drug substances are discussed below in greater detail. Physical description: The description should include appearance, colour, and physical state. Solid forms should be identified as being crystalline or amorphous. Solubilities/quantitative aqueous pH solubility profile:
13
465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507
The solubility should be provided in a number of common solvents (e.g., water, alcohols, chloroform, acetone, etc.). The solubilities over the physiological pH range (pH 1 to 8) in several buffered media should also be provided. Phrases such as sparingly soluble or freely soluble should be quantitatively defined or a literature reference can be provided (e.g., as per USP). If this information is not readily available (e.g., literature references, Open Drug Master File), it should be generated in-house. The dose/solubility volume should be provided. The dose/solubility volume 1 is calculated based on the minimum concentration of the drug (in mg/mL), in the largest dosage strength, determined in the physiological pH range (pH 1 to 8) and temperature (37 0.5C). High solubility drugs are those with a dose/solubility volume of less than or equal to 250 mL. For example, Compound A has as its lowest solubility at 37 0.5C, 1.0 mg/mL at pH 7, and is available in 100 mg, 200 mg, and 400 mg strengths. This drug would be considered a low solubility drug as its dose/solubility volume is greater than 250 mL (400 mg/1.0 mg/mL = 400 mL). Polymorphs: If the potential for polymorphism is a concern, results from an investigation of several batches of the drug substance, recrystallized from several solvents, should be provided to determine if the drug substance exists in more than one crystalline form. The study should include the characterization of the batch(es) used in the clinical and/or comparative bioavailability studies, using a suitable method (e.g., X-ray Diffraction (XRD), Differential Scanning Calorimetry (DSC), Fourier Transform Infrared Spectroscopy (FTIR)). The absence of the potential for polymorphism can further be confirmed by providing the results of a literature search. If the results of studies conducted on the physical and chemical properties of the various crystalline forms indicate that there is a preferred polymorph, criteria should be incorporated into the drug substance specification to ensure polymorphic equivalence of the commercial material to the batch(es) used in the clinical and/or comparative bioavailability studies. Generally, controls on polymorphism are not a concern for drug substances that are considered highly soluble. Justification for the exclusion of the controls for polymorphism should be provided. Polymorphism can also include solvation or hydration products (also known as pseudopolymorphs). If the drug substance is used in a solvated form, the following information should be provided: (a) (b) specifications for the solvent-free drug substance, if that compound is a synthetic precursor; specifications for the solvated drug substance including appropriate limits on the weight ratio of drug substance to solvent (with data to support the proposed limits); and a description of the method used to prepare the solvate.
(c)
Particle size distribution:
Immediate Release Solid Oral Dosage Forms: Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation, Center for Drug Evaluation and Research (CDER), November 1995.
14
508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554
For poorly soluble drug substances, the particle size distribution of the material can have an effect on the in vitro and/or in vivo behaviour of the drug product. Particle size can also be important in dosage form performance (e.g. delivery of inhalation products), achieving uniformity of content in low-dose tablets (e.g., 2 mg or less), desired smoothness in ophthalmic preparations, and stability of suspensions. If particle size distribution is important (e.g., as in the above cases), results from an investigation of several batches of the drug substance should be provided, including characterization of the batch(es) used in the clinical and/or comparative bioavailability studies. If applicable, the acceptance criteria should include controls on the particle size distribution to ensure consistency with the material in the batch(es) used in the clinical and/or comparative bioavailability studies (e.g., limits for d10 , d50 , and d90 ). This criteria should be established statistically based on the standard deviation of the test results from the previously mentioned studies. The following is provided for illustrative purposes as possible acceptance criteria for particle size limits: d10 d50 d90 NMT 10% of total volume less than X m XX m - XXX m NLT 90% of total volume less than XXXX m
Other controls on particle size can be considered acceptable, if scientifically justified. Reference Guidances: Q6A S 2 Manufacture If a Drug Master File (DMF) is filed with Health Canada and cross-referenced for certain proprietary information (e.g., sections S 2.2, S 2.3, S 2.4, and S 2.6), provide the DMF number assigned by Health Canada. It should be ensured that the information included in the DMF is up to date (e.g., updated every two years) and that the data has been received by Health Canada. Copies of the letters of access should be provided under the Regional Information section. If a Canadian agent is used by the DMF Holder, a letter from the DMF Holder should be submitted allowing the agent to act on their behalf, rather than the letter coming from the Canadian agent. S 2.1 Manufacturer(s) The name, address, and responsibility of each manufacturer, including contractors, and each proposed production site or facility involved in manufacturing and testing should be provided. This includes the facilities involved in the fabrication, packaging, labelling, testing, importing, storage, and distribution of the drug substance. If certain companies are responsible only for specific steps (e.g., milling of the drug substance), this should be indicated. The list of manufacturers should specify the actual production or manufacturing site(s) involved, rather than the administrative offices. S 2.2 Description of Manufacturing Process and Process Controls
15
555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600
A flow diagram of the synthetic process(es) should be provided that includes molecular formulae, weights, yield ranges, chemical structures of starting materials, intermediates, reagents and drug substance reflecting stereochemistry, and identifies operating conditions and solvents. A sequential procedural narrative of the manufacturing process should be submitted. The narrative should include, for example, quantities of raw materials, solvents, catalysts and reagents reflecting the representative batch scale for commercial manufacture, identification of critical steps, process controls, equipment and operating conditions (e.g., temperature, pressure, pH, time). Alternate processes should be explained and described with the same level of detail as the primary process. Reprocessing steps should be identified and justified. Any data to support this justification should be either referenced or filed in S 2.5. The information on the manufacturing process should start from commercially available or wellcharacterized starting materials. The manufacturing process for the batch(es) used in the clinical and/or comparative bioavailability studies should be representative of the process for commercial purposes (i.e., laboratory scale batches are not considered acceptable). If the drug substance is prepared as sterile, a complete description should be provided for the method used in the sterilization. The controls used to maintain the sterility of the drug substance during storage and transportation should be provided. In addition to the above information, the data provided for a drug substance produced by fermentation should include: (a) (b) (c) (d) source and type of micro-organism used; composition of media; precursors; additional details on how the reaction conditions are controlled (e.g., times, temperatures, rates of aeration, etc.); and name and composition of preservatives.
(e)
For drug substances of plant origin, include a description of the botanical species and the part of plant used, the geographical origin and, where relevant, the time of year harvested. The nature of chemical fertilizers, pesticides, fungicides, etc. should be recorded, if these have been employed during cultivation. It may be necessary to include limits for residues resulting from such treatments in the drug substance specification. Absence of toxic metals and radioactivity may also have to be confirmed.
16
601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647
Draft date: 2001/07/18 17
S 2.3 Control of Materials Materials used in the manufacture of the drug substance (e.g., raw materials, starting materials, solvents, reagents, catalysts) should be listed identifying where each material is used in the process. Information on the quality and control of these materials should be provided. Information demonstrating that materials meet standards appropriate for their intended use should be provided, as appropriate. Copies of the specifications for the materials used in the synthesis, fermentation, extraction, isolation, and purification steps should be provided in the drug submission. Drug substances of animal origin should be free of Bovine Spongiform Encephalopathy (BSE) / Transmissible Spongiform Encephalopathy (TSE) and a letter of attestation confirming this should be included with the drug submission. Details in A2. Reference Guidances: Q6A S 2.4 Controls of Critical Steps and Intermediates Critical Steps: Tests and acceptance criteria (with justification including experimental data) performed at critical steps identified in S2.2 of the manufacturing process to ensure that the process is controlled should be provided. Intermediates: Information on the quality and control of intermediates isolated during the process should be provided. Generally, these specifications would include tests and acceptance criteria for identity, purity, and potency, where applicable. Well-defined controls of potential impurities should be included for the starting material. Special consideration should be given to potential isomeric impurities in the starting material, as such contaminants that could be carried through the synthesis to the drug substance. Reference Guidances: Q6A S 2.5 Process Validation and/or Evaluation Process validation and/or evaluation studies for aseptic processing and sterilisation should be included. It is expected that the manufacturing processes for all drug substances are properly controlled. Justification should be provided for alternate manufacturing processes. S 2.6 Manufacturing Process Development
648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694
A description and discussion should be provided of the significant changes made to the manufacturing process and/or manufacturing site of the drug substance used in producing nonclinical, clinical, scale-up, pilot, and, if available, production scale batches. Reference should be made to the drug substance data provided in section S 4.4. The above information should also be provided for comparative (e.g., for existing drugs) and stability batches. Reference Guidances: Q3A S 3 Characterisation S 3.1 Elucidation of Structure and other Characteristics Confirmation of structure based on e.g., synthetic route and spectral analyses should be provided. The Quality Summary should include a list of the studies performed and a conclusion from the studies (e.g., if the results support the proposed structure). The drug submission should include copies of the spectra, peak assignments, and an interpretation of the data. The studies carried out to elucidate and/or confirm the chemical structure of New Chemical Entities normally include elemental analysis, Infrared (IR), Ultraviolet (UV), Nuclear Magnetic Resonance (NMR), and Mass Spectra (MS) studies. Other tests could include X-ray diffraction (XRD). For existing drugs (e.g., generics), it is generally sufficient to provide copies of the IR and UV spectra of the drug substance from the proposed suppliers run concomitantly with suitable reference standard. A suitable primary reference standard could be obtained from the Schedule B compendia (e.g., USP, Ph.Eur, BP, etc.) or a batch of the drug substance that has been fully characterized (e.g., IR, UV, NMR, MS, etc.). See section S 5 for further details on References Standards or Materials. When a drug substance is chiral, it should be specified whether specific stereoisomers or a mixture of stereoisomers have been used in the nonclinical and clinical studies, and information should be given as to the stereoisomer of the drug substance that is to be used in the final product intended for marketing. A discussion should be included of the possible isomers that can result from the manufacturing process, the steps where they were introduced, and a summary of the results of the studies carried out to investigate the physical, chemical, and biological properties of these isomers. If there is a preferred isomer or isomeric mixture, the drug substance specification should include a test to ensure isomeric identity and purity. If the drug substance is a single isomer or a fixed ratio of isomers, provide the rationale for this decision, including a discussion of the material that was used in the clinical and/or comparative bioavailability study. For existing drugs (e.g., generics), include a summary of any comparative studies performed.
18
695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741
For drug substances that contain an asymmetric centre, where there has not been any information provided regarding the manufacture of the starting material through which it has been introduced, results of a study should be submitted demonstrating that the material exists as a racemic mixture (e.g., specific optical rotation). It is recognized that some drugs (e.g., certain antibiotics, enzymes, and peptides) present difficulties with respect to structural investigation. In such cases, more emphasis should be placed on the purification and the specification for the drug substance. If a drug substance consists of more than one component, the physicochemical characterization of the components and their ratio should be submitted. If, based the structure of the drug substance, there is not a potential for isomerism, it could be sufficient to include a statement to this effect. Reference Guidances: Q6A Stereochemical Issues in Chiral Drug Development S 3.2 Impurities Information on impurities should be provided. The study of impurities can be considered one of the most important aspects of the Quality portion of the drug submission. The sponsor should provide a discussion of the potential and actual impurities arising from the synthesis, manufacture, and/or degradation. The tables in Health Canadas Quality Summary template can be used to summarize the information on impurities (e.g., names, structures, origin, results, etc.). The origin refers to how the impurity was introduced (e.g., Synthetic intermediate from Step 4 of the synthesis, Potential by-product due to rearrangement from Step 6 of the synthesis, etc.). It should also be indicated if the impurity is a metabolite of the drug substance. The basis for setting the acceptance criteria for the impurities should be provided. This is established by considering the identification and qualification thresholds for drug-related impurities (e.g., starting materials, by-products, intermediates, chiral impurities, or degradation products) and the concentration limits for process-related impurities (e.g., residual solvents) as per the applicable ICH guidance document (e.g., Q3A, Q3C). These thresholds are determined on the basis of potential exposure to the impurity, i.e., by the maximum daily dose (MDD) of the drug substance. For drugs available in multiple dosage forms and strengths, having different MDD values, it is imperative that the thresholds and corresponding controls for each of the presentations be considered to ensure that the risks posed by impurities have been addressed. This is normally achieved by using the highest potential daily MDD, rather than the maintenance dose. For parenteral products, the maximum hourly dose of the drug substance should also be included. The acceptance criteria is also set taking into consideration the actual levels of impurities found in several batches of the drug substance from each source, including the levels found in the batches used for the nonclinical, clinical, and comparative studies. For quantitative tests, it should be ensured that actual numerical results are provided rather than vague statements such as within limits or conforms. In the cases where a large number of batches have been tested, it is acceptable to summarize the total number of batches tested with a range of analytical results.
Draft date: 2001/07/18 19
742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788
Qualifying limits for specified impurities is normally based on the levels found in the nonclinical and clinical batches at the time the studies were conducted, rather than levels observed on stability or levels found in subsequent batches manufactured according to the proposed commercial process. Results on the drug product can also be presented for comparative batches (e.g., for a comparative purity study of a generic product against the Canadian reference product). It is recognized by the compendia that drug substances can be obtained from various sources, and thus can contain impurities not considered during the preparation of the monograph. Furthermore, a change in the production or source may give rise to impurities that are not adequately controlled by the published compendial monograph. As a result, each drug submission is reviewed independently to consider the potential impurities that may arise from the proposed route(s) of synthesis. For these reasons, the ICH limits for unspecified impurities (e.g., Not More Than (NMT) 0.1% for drug substances having a maximum daily dose #2 g/day) are generally recommended, rather than the general limits for unspecified impurities that appear in the compendial monograph that could be potentially higher than the ICH limit. Depending on the nature of the drug substance, and the extent of the chemical modification steps, the principles on the control of impurities (e.g., identification and qualification) can also be extended to drug substances of semi-synthetic origin. As an illustrative example, a drug substance whose precursor molecule was derived from a fermentation process, or a natural product of plant or animal origin, and has subsequently undergone several chemical modification reactions generally would fall within this scope, whereas a drug whose sole chemical step was the formation of a salt from a fermentation product generally would not fall within this scope. It is understood that there is some latitude for these types of drug substances (e.g., NMT 0.2% for unspecified impurities may be appropriate, rather than NMT 0.1%). If there are identified impurities specified in a compendial monograph (e.g., as in a Ph.Eur. Transparency Monograph) that are not monitored by the proposed routine method (e.g., House method), a justification should be provided for their exclusion. If acceptable justification cannot be provided, it should be demonstrated that the alternate method is capable of detecting the impurities specified in the compendial monograph at an acceptable level (e.g., 0.1%). Reference Guidances: Q3A, Q3C, Q6A Identification, Qualification, and Control of Related Impurities in New Drugs Identification, Qualification, and Control of Related Impurities in Existing Drugs Stereochemical Issues in Chiral Drug Development S 4 Control of the Drug Substance S 4.1 Specification The specification for the drug substance should be provided. As defined in ICHs Q6A guidance document, a specification is a list of tests, references to analytical procedures, and appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for the tests described. It establishes the set of criteria to which a drug substance should conform to be considered acceptable for its intended use. Conformance to specifications means that the drug substance, when tested according to the listed analytical procedures, will meet the listed acceptance
Draft date: 2001/07/18 20
789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835
criteria. Specifications are critical quality standards that are proposed and justified by the manufacturer and approved by regulatory authorities as conditions of approval. A copy of the drug substance specification from the company responsible for release testing should be provided, dated and signed by authorized personnel (i.e., the person in charge of the Quality Control department). The specification reference number, version, and date should be provided for version control purposes. The standard declared by the sponsor could be a Schedule B compendial standard (e.g., USP, Ph.Eur., BP, etc.), Manufacturers or House Standard, Prescribed Standard (e.g., Canadian Standard Drugs in Division C.06 of the Food and Drug Regulations), or a Professed Standard. Although a Schedule B compendial monograph may exist, a sponsor can choose to use a Manufacturers Standard which indicates that the material may differ in some respect from the compendial standard. However, according to section C.01.011 of the Food and Drug Regulations, no person shall use a manufacturers standard for a drug that provides (a) a lesser degree of purity than the highest degree of purity and (b) a greater variance in potency than the least variation in potency, provided for that drug in any publication mentioned in Schedule B to the Act. Therefore, if a manufacturers standard is used, the controls on purity (e.g., limits on specified impurities) and potency should be as tight as the most stringent of those listed in the Schedule B compendial monographs. If the drug submission is for a non-official drug (e.g., where neither a Prescribed nor a Schedule B compendial standard exists), a professed standard is used and the product labelling for such products does not carry any standard. The specification can be summarized according to Health Canadas Quality Summary template including the Tests, Method Types, Sources, and Code Number/Version/Date. The acceptance criteria should also be provided in the summary of the specification. The Method Type should indicate the kind of analytical procedure used (e.g., visual, IR, UV, HPLC, laser diffraction, etc.); the Source refers to the origin of the analytical procedure (e.g., USP, Ph.Eur., BP, House, etc.); and the Code Number/Version/Date should be provided for version control purposes. ICHs Q6A guidance document outlines recommendations for a number of universal and specific tests and criteria for drug substances. Reference Guidances: Q3A, Q3C, Q6A S 4.2 Analytical Procedures The analytical procedures used for testing the drug substance should be provided. Copies of the House analytical procedures used during the drug development (if used to support testing results in the drug submission) as well as those proposed for routine testing should be provided. The tables in Health Canadas Quality Summary template can be used to summarize the analytical procedures. Unless modified, it is not necessary to provide copies of Schedule B compendial analytical procedures. Although HPLC is normally considered the method of choice for determining drug-related impurities, other chromatographic methods such as GC and TLC can also be used, if appropriate. For impurity
Draft date: 2001/07/18 21
836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882
methods, reference standards should be prepared for each of the identified impurities, particularly those known to be toxic, and the concentration of the impurities quantitated against their own reference standards. It is considered acceptable to use the drug substance as an external standard to estimate the levels of impurities, provided the response factors of those impurities are sufficiently close to that of the drug substance (e.g., greater than 80%). In cases where the response factor is not close, it may still be acceptable to use the drug substance, provided a correction factor is applied or the impurities are, in fact, being overestimated. Unspecified impurities should be quantitated using a solution of the drug substance as the reference standard at a concentration corresponding to the limit established for individual unspecified impurities (e.g., 0.1%). The system suitability tests (SSTs) are an integral part of chromatographic analytical procedures. As a minimum, HPLC and GC methods should include SSTs for resolution and repeatability. For HPLC methods to control drug-related impurities, this is typically done using a solution of the drug substance with a concentration corresponding to the limit for unspecified impurities. Resolution of the two closest eluting peaks is generally recommended. However, choice of alternate peaks can be used if justified (e.g., choice of a toxic impurity). In accordance with the USP General Chapter on Chromatography and Health Canadas guidance document Acceptable Methods, the repeatability test should include an acceptable number of replicate injections (i.e., five or six). For TLC methods, the SSTs should verify the sensitivity and ability of the system to separate (e.g., by applying a spot corresponding to the drug substance spiked at a concentration corresponding to the limit of unspecified impurities). Reference Guidances: Q2A Acceptable Methods S 4.3 Validation of Analytical Procedures Analytical validation information, including experimental data for the analytical procedures used for testing the drug substance, should be provided. Copies of the validation reports for the analytical procedures used during the drug development (if used to support testing results in the drug submission) as well as those proposed for routine testing should be provided. The tables in Health Canadas Quality Summary template can be used to summarize the validation information. As outlined in Health Canadas guidance document Acceptable Methods, partial revalidation is necessary for methods that appear in a Schedule B compendial monograph. These revalidation criteria are recognized by other Regulatory Agencies and the compendia themselves. The compendial methods, as published, are typically validated using a drug substance or a drug product originating from a specific manufacturer. Different sources of the same drug substance or drug product can contain impurities and degradation products that were not considered during the development of the monograph. In general, revalidation is not necessary for Schedule B compendial potency methods. However, specificity of the compendial potency method should be demonstrated if there are any potential impurities that are not specified in the compendial monograph. If a Schedule B compendial method is used to control drug-related impurities that are not specified in the monograph, full validation is expected.
22
883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929
If a Schedule B compendial standard is claimed and a House method is used in lieu of the compendial method (e.g., for potency or for specified impurities), equivalency of the House and compendial methods should be demonstrated. This could be accomplished by performing duplicate analyses of one sample by both methods and providing the results from the study. With respect to the control of residual solvents, it is acknowledged that GC methods for determining residual solvents are generally sensitive, linear, and reproducible. In past experience, it has been found that a sponsor will use essentially the same GC method to determine residual solvents in a number of drug substances and drug products. Therefore, although it is expected that a company will initially perform full validation of the methods used to determine residual solvents, it is acceptable that only limited validation data be submitted (e.g., recovery, repeatability, limit of detection, limit of quantitation, and selectivity of the method). Recovery and repeatability should be determined using a sample of the drug substance or drug product spiked with the residual solvents at their acceptance criteria. Reference Guidances: Q2A, Q2B Acceptable Methods S 4.4 Batch Analyses Description of batches and results of batch analyses should be provided. This would include information such as batch number, batch size, date and site of production, etc. on relevant drug substance batches (e.g., used in nonclinical, clinical, comparative, stability, pilot, scale-up, and, if available, production-scale batches) used to establish the specification(s) and evaluate consistency in manufacturing. Analytical results tested by the company responsible for release testing should be provided from at least two batches from each proposed manufacturing site of the drug substance. The testing results should include the batch(es) used in the nonclinical, clinical and/or comparative bioavailability studies. Copies of the certificates of analyses for these batches should be provided in the drug submission and the company responsible for generating the testing results should be identified. The discussion of results should focus on observations noted for the various tests, rather than reporting comments such as All tests meet specifications. This should include ranges of analytical results and any trends that were observed. For quantitative tests (e.g., as in individual and total impurity tests and potency tests), it should be ensured that actual numerical results are provided rather than vague statements such as within limits or conforms. A discussion and justification should be provided for any incomplete analyses (e.g., results not tested according to the proposed specification). Reference Guidances: Q3A, Q3C, Q6A S 4.5 Justification of Specification Justification for the drug substance specification should be provided.
23
930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976
This should include a discussion on the inclusion of certain tests, evolution of tests, analytical procedures, and acceptance criteria, differences from compendial standard, etc.. If the Schedule B compendial methods have been modified or replaced, a discussion should be included. The justification for certain tests, analytical procedures, and acceptance criteria may have been discussed in other sections of the drug submission (e.g., impurities, particle size) and do not need to be repeated here, although a cross-reference to their location should be provided. Reference Guidances: Q3A, Q3C, Q6A S 5 Reference Standards or Materials Information on the reference standards or reference materials used for testing of the drug substance should be provided. The source(s) of the reference standards or materials used in the testing of the drug substance should be provided (e.g., for the identification, purity, potency tests). Primary reference standards can be obtained from official sources such those recognized in the Schedule B compendia. Primary reference standards from official sources do not need further structural elucidation. A primary standard could also be validated as a batch of drug substance that has been fully characterized and structurally elucidated (e.g., IR, UV, NMR, MS, etc.). A secondary (or House) reference standard can be used by providing a copy of its certificate of analysis and validating it against a suitable primary reference standard (e.g., by providing legible copies of the IR and UV of the secondary and primary reference standards run concomitantly). A secondary reference standard is often characterized and evaluated for its intended purpose with additional procedures other than those used in routine testing (e.g., if additional solvents are used for purification during the manufacturing process that are not used for routine purposes). A brief description of the manufacture process of the secondary reference standard should be provided, if it differs from commercial process for the drug substance. Reference Guidances: Q6A Acceptable Methods S 6 Container Closure System A description of the container closure system(s) should be provided, including the identity of materials of construction of each primary packaging component, and their specifications. The specifications should include description and identification (and critical dimensions with drawings, where appropriate). Non-compendial methods (with validation) should be included, where appropriate. For non-functional secondary packaging components (e.g., those that do not provide additional protection), only a brief description should be provided. For functional secondary packaging
Draft date: 2001/07/18 24
977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023
components, additional information should be provided. The suitability should be discussed with respect to, for example, choice of materials, protection from moisture and light, compatibility of the materials of construction with the drug substance, including sorption to container and leaching, and/or safety of materials of construction. S 7 Stability As outlined in ICHs Q1A guidance document, the purpose of stability testing is to provide evidence on how the quality of a drug substance varies with time under the influence of a variety of environmental factors such as temperature, humidity, and light, and to establish a re-test period for the drug substance and recommended storage conditions. Reference Guidances: Q1A, Q1B Stability Testing of Existing Drug Substances and Products S 7.1 Stability Summary and Conclusions The types of studies conducted, protocols used, and the results of the studies should be summarised. The summary should include results, for example, from forced degradation studies and stress conditions, as well as conclusions with respect to storage conditions and retest date or shelf-life, as appropriate. Stress testing: As outlined ICHs Q1A guidance document, stress testing of the drug substance can help identify the likely degradation products, which can in turn help establish the degradation pathways and the intrinsic stability of the molecule and validate the stability indicating power of the analytical procedures used. The nature of the stress testing will depend on the individual drug substance and the type of drug product involved. The table in Health Canadas Quality Summary template can be used to summarize the results from the stress testing. This summary should include the treatment conditions (e.g., concentrations of solutions prepared, storage temperatures and durations) and the observations for the various test parameters (e.g., potency, degradation products). Accelerated and long term testing: The conditions for stability testing of new drug substances are outlined in ICHs Q1A guidance document. The following storage conditions and minimum data at the time of submission are recommended by ICHs Q1A guidance document for the Primary Batches. When significant change occurs at any time during 6 months testing at the accelerated storage condition, additional testing at the intermediate storage condition should be conducted and evaluated against significant change criteria. See ICHs Q1A guidance document for definition of significant change.
25
1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067
Study Long term Intermediate Accelerated
Storage Condition 25C 2C / 60% RH 5% RH 30C 2C / 60% RH 5% RH 40C 2C / 75% RH 5% RH
Minimum Time Period Covered by Data at Submission 12 months 6 months 6 months
RH = relative humidity Other conditions are outlined in the ICHs Q1A guidance document for drug substances intended for storage in a refrigerator and those intended for storage in a freezer. Drug substances intended for storage below -20C should be treated on a case-by-case basis. For existing drugs (e.g., generics), available information on the stability of the drug substance under accelerated and long term conditions should be provided, including information in the public domain or obtained from DMF Holders. The source of the information should be identified. In certain cases, information available in the public domain may be sufficient to establish an appropriate re-test period, e.g., when a substantial body of evidence exists that establishes that the drug substance is inherently stable. In all instances, sponsors are encouraged to provide all relevant information available on the stability of the drug substance. The information on the stability studies should include details such as storage conditions, batch number, batch size, container closure system, and completed (and proposed) test intervals. The discussion of results should focus on observations noted for the various tests, rather than reporting comments such as All tests meet specifications. This should include ranges of analytical results and any trends that were observed. For quantitative tests (e.g., as in individual and total degradation product tests and potency tests), it should be ensured that actual numerical results are provided rather than vague statements such as within limits or conforms. Proposed storage conditions and re-test period: The proposed storage conditions with suitable tolerances (e.g., a temperature range with upper and lower criteria) and re-test period for the drug substance should be provided. When the drug substance has been shown to be stable (e.g., under the ICH conditions with long term studies at 25EC 2EC/60% RH 5% RH and accelerated studies at 40EC 2EC/75% RH 5% RH), the following storage recommendation would generally be considered acceptable: "Store at controlled room temperature (15EC to 30EC)." Based on the results of the stability evaluation, other storage precautions may be warranted (e.g., "Protect from light", "Protect from moisture"). Re-test periods are generally one or two years. A re-test period longer than two years should be fully supported by the results from stability studies conducted under the conditions recommended by ICHs Q1A guidance document. After this period, a batch of drug substance destined for use in the manufacture
Draft date: 2001/07/18 26
1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114
of a drug product should be re-tested for compliance with the specification and then used immediately (e.g., within 30 days). If re-tested, the batch does not receive the period of time established for the re-test period. For drug substances known to be labile (e.g., certain antibiotics), it is more appropriate to establish a shelf life than a re-test period. Limited extrapolation of the real time data from the long term storage condition beyond the observed range to extend the re-test period can be undertaken at approval time, if justified. S 7.2 Post-approval Stability Protocol and Stability Commitment The post-approval stability protocol and stability commitment should be provided. When available long term stability data on primary batches do not cover the proposed shelf life granted at the time of approval, a commitment should be made to continue the stability studies post-approval in order to firmly establish the shelf life. The long term stability studies for the Commitment Batches should be conducted through the proposed shelf life (and the accelerated studies for six months) on at least three production batches of each strength (or two production batches of each strength for existing drugs). The stability protocol for the Commitment Batches and should include, but not limited to: (a) (b) (c) (d) (e) Number of batches and batch sizes; Tests and acceptance criteria; Container closure system(s); Testing frequency; and Storage conditions (and tolerances) of samples
Any differences in the stability protocols used for the primary batches and those proposed for the Commitment Batches or should be scientifically justified. S 7.3 Stability Data Results of the stability studies (e.g., forced degradation studies and stress conditions) should be presented in an appropriate format such as tabular, graphical, or narrative. Information on the analytical procedures used to generate the data and validation of these procedures should be included. This would include the actual stability results (i.e., raw data) used to support the proposed re-test period or shelf life. For quantitative tests (e.g., as in individual and total degradation product tests and potency tests), it should be ensured that actual numerical results are provided rather than vague statements such
Draft date: 2001/07/18 27
1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161
as within limits or conforms. P DRUG PRODUCT P 1 Description and Composition of the Drug Product A description of the drug product and its composition should be provided. The information provided should include, for example: (a) Description of the dosage form; The description of the dosage form should include the physical description, available strengths, release mechanism, as well as any other distinguishable characteristics (e.g., The proposed drug product is available as oval, round, immediate-release, aqueous film-coated tablet in three strengths (5 mg, 10 mg, and 20 mg). The two higher strengths include a vertical score line to facilitate the breaking of the tablets.). (b) Composition, i.e., list of all components of the dosage form, and their amount on a per unit basis (including overages, if any) the function of the components, and a reference to their quality standards (e.g., compendial monographs or manufacturers specifications); The composition should express the quantity of each component on a per unit basis (e.g., mg per tablet, mg per mL, mg per vial, etc.) and percentage basis, including a statement of the total weight or measure of the dosage unit. This should include all components used in the manufacturing process, regardless if they appear in the final drug product (e.g., solvents, nitrogen, silicon for stoppers, etc.). If the drug product is formulated using an active moiety, then the composition for the active ingredient should be clearly indicated (e.g., 1 mg of active ingredient base = 1.075 mg active ingredient hydrochloride). All overages should be clearly indicated (e.g., Contains 2% overage of the drug substance to compensate for manufacturing losses.). The components should be declared by their proper or common names, Quality standards (e.g., USP, Ph.Eur., House, etc.) and, if applicable, their grades (e.g., Microcrystalline Cellulose NF (PH 102)). The qualitative composition should be provided for all proprietary components or blends (e.g., capsule shells, colouring blends, imprinting inks, etc.). This information is used for product labelling purposes. Reference to a Drug Master File can be provided for the actual quantitative composition. The function of each component (e.g., diluent/filler, binder, disintegrant, lubricant, glidant, granulating solvent, coating agent, antimicrobial preservative, etc.) should be provided. (c) Description of accompanying reconstitution diluent(s); and For drug products supplied with reconstitution diluent(s) that are not commercially available in Canada or have not been reviewed and approved in connection with another drug submission with
Draft date: 2001/07/18 28
1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208
Health Canada, information on the diluent(s) should be provided in a separate Drug Product (P) portion, as appropriate. (d) Type of container and closure used for the dosage form and accompanying reconstitution diluent, if applicable. The description for the container closure used for the dosage form (and accompanying reconstitution diluent, if applicable) should be brief with further details provided under P 7 Container Closure System (e.g., The product is available in HDPE bottles with polypropylene caps and in PVC/Aluminum foil unit dose blisters.). Reference Guidances: Q6A P 2 Pharmaceutical Development The Pharmaceutical Development section should contain information on the development studies conducted to establish that the dosage form, the formulation, manufacturing process, container closure system, microbiological attributes and usage instructions are appropriate for the purpose specified in the application. The studies described here are distinguished from routine control tests conducted according to specifications. Additionally, this section should identify and describe the formulation and process attributes (critical parameters) that can influence batch reproducibility, product performance and drug product quality. Supportive data and results from specific studies or published literature can be included within or attached to the Pharmaceutical Development section. Additional supportive data can be referenced to the relevant nonclinical or clinical sections of the application. Reference Guidances: Q6A P 2.1 Components of the Drug Product P 2.1.1 Drug Substance The compatibility of the drug substance with excipients listed in P1 should be discussed. Additionally, key physicochemical characteristics (e.g., water content, solubility, particle size distribution, polymorphic or solid state form) of the drug substance that can influence the performance of the drug product should be discussed. For combination products, the compatibility of drug substances with each other should be discussed. P 2.1.2 Excipients The choice of excipients listed in P1, their concentration, their characteristics that can influence the drug product performance should be discussed relative to their respective functions. Alternates for excipients are generally not accepted. Ranges for excipients normally are not accepted, unless supported by appropriate process validation data. Where relevant, compatibility study results (e.g., primary
Draft date: 2001/07/18 29
1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255
and secondary compatibility of an amine drug with lactose) should be included to justify the choice of excipients. Specific details should be provided where necessary (e.g., use of potato or corn starch). Where antioxidants are included in the formulation, the effectiveness of the proposed concentration of the antioxidant should be justified and verified by appropriate studies. A certification should be provided that none of the excipients which appear in the drug product are prohibited for use in drugs by the Canadian Food and Drugs Act and Regulations. P 2.2 Drug Product P 2.2.1 Formulation Development A brief summary describing the development of the drug product should be provided, taking into consideration the proposed route of administration and usage. The differences between clinical formulations and the formulation (i.e., composition) described in P1 should be discussed. Results from comparative in vitro studies (e.g., dissolution) or comparative in vivo studies (e.g., bioequivalence) should be discussed, when appropriate. The tables in Health Canadas Quality Summary template can be used to summarize the above information. When assessing the data elements needed for multiple strengths, Health Canadas policy Bioequivalence of Proportional Formulations: Solid Oral Dosage Forms should be consulted. P 2.2.2 Overages Any overages in the formulation(s) described in P1 should be justified. Overages for the sole purpose of extending the shelf life of the drug product are generally not acceptable. P 2.2.3 Physicochemical and Biological Properties Parameters relevant to the performance of the drug product, such as pH, ionic strength, dissolution, redispersion, reconstitution, particle size distribution, aggregation, polymorphism, rheological properties, biological activity or potency, and/or immunological activity, should be addressed. P 2.3 Manufacturing Process Development The selection and optimisation of the manufacturing process described in P3.3, in particular its critical aspects, should be explained. Where relevant, the method of sterilisation should be explained and justified. Differences between the manufacturing process(es) used to produce pivotal clinical batches and the process described in P3.3 that can influence the performance of the product should be
Draft date: 2001/07/18 30
1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302
discussed. The rationale for choosing the particular type of drug delivery system should be provided (e.g., matrix or membrane based controlled delivery, liposomal, microemulsion, depot injection). The scientific rationale for the choice of the manufacturing, filling, and packaging processes that can influence drug product quality and performance should be explained (e.g., wet granulation using high shear granulator). Any developmental work undertaken to protect the drug product from deterioration should also be included (e.g., protection from light or moisture). The scientific rationale for the selection, optimization, and scale-up of the manufacturing process described in P 3.3 should be explained, in particular the critical aspects (e.g., rate of addition of granulating fluid, massing time). The equipment should be identified by type and working capacity. P 2.4 Container Closure System The suitability of the container closure system (described in P7) used for the storage, transportation (shipping) and use of the drug product should be discussed. This discussion should consider, e.g., choice of materials, protection from moisture and light, compatibility of the materials of construction with the dosage form (including sorption to container and leaching) safety of materials of construction, and performance (such as reproducibility of the dose delivery from the device when presented as part of the drug product). See section P 7 for a discussion on the information that could be included for the qualification of the container closure system. P 2.5 Microbiological Attributes Where appropriate, the microbiological attributes of the dosage form should be discussed, including, for example, the rationale for not performing microbial limits testing for non-sterile products and the selection and effectiveness of preservative systems in products containing antimicrobial preservatives. For sterile products, the integrity of the container closure system to prevent microbial contamination should be addressed. Where an antimicrobial preservative is included in the formulation, the effectiveness of the agent should be justified and verified by appropriate studies using a batch of the drug product. If the lower bound for the proposed acceptance criteria for the assay of the preservative is less than 90.0%, the effectiveness of the agent should be established with a batch of the drug product containing a concentration of the antimicrobial preservative corresponding to the lower proposed acceptance criteria. As outlined in ICHs Q1A guidance document, a single primary stability batch of the drug product should be tested for antimicrobial preservative effectiveness (in addition to preservative content) at the proposed shelf life for verification purposes, regardless of whether there is a difference between the release and shelf life acceptance criteria for preservative content. If this information is not available at the time of submission, a commitment should be provided that a single
Draft date: 2001/07/18 31
1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349
primary stability batch will be tested for antimicrobial preservative effectiveness at the proposed shelf life. P 2.6 Compatibility The compatibility of the drug product with reconstitution diluent(s) or dosage devices (e.g., precipitation of drug substance in solution, sorption on injection vessels, stability) should be addressed to provide appropriate and supportive information for the labeling. Where sterile, reconstituted products are to be further diluted, compatibility should be demonstrated with all diluents over the range of dilution proposed in the labelling. These studies should preferably be conducted on aged samples. Where the labelling does not specify the type of containers, compatibility (with respect to parameters such as appearance, pH, assay, levels of individual and total degradation products, sub-visible particulate matter and extractables from the packaging components) should be demonstrated in glass, PVC, and polyolefin containers. However, if one or more containers are identified in the labelling, compatibility of admixtures needs to be demonstrated only in the specified containers. Studies should cover the duration of storage reported in the labelling (e.g., 24 hours under controlled room temperature and 72 hours under refrigeration). Where the labelling specifies co-administration with other drugs, compatibility should be demonstrated with respect to the principal drug as well as the co-administered drug (i.e., in addition to other aforementioned parameters for the mixture, the assay and degradation levels of each co-administered drug should be reported). For existing drugs (e.g., generics), if levels of impurities or other parameters warrant, these studies should be carried out in parallel with the reference product to adequately qualify the impurity and other limits proposed in the drug product specification(s). P 3 Manufacture If a Drug Master File (DMF) is filed with Health Canada and cross-referenced for certain proprietary information, provide the DMF number assigned by Health Canada. It should be ensured that the information included in the DMF is up to date (e.g., updated every two years) and that the data has been received by Health Canada. Copies of the letters of access should be provided under the Regional Information section. If a Canadian agent is used by the DMF Holder, a letter from the DMF Holder should be submitted allowing the agent to act on their behalf, rather than the letter coming from the Canadian agent. P 3.1 Manufacturer(s) The name, address, and responsibility of each manufacturer, including contractors, and each proposed production site or facility involved in manufacturing and testing should be provided. This includes the facilities involved in the fabrication, packaging, labelling, testing, importing, storage, and distribution of the drug product. If certain companies are responsible only for specific steps (e.g., manufacturing of an intermediate), this should be indicated. The list of manufacturers should specify the actual production or manufacturing site(s) involved, rather than the administrative offices.
Draft date: 2001/07/18 32
1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396
Draft date: 2001/07/18 33
P 3.2 Batch Formula A batch formula should be provided that includes a list of all components of the dosage form to be used in the manufacturing process, their amounts on a per batch basis, including overages, and a reference to their quality standards . The batch formula should express the quantity of each component on a per batch basis including a statement of the total weight or measure of the batch. This should include all components used in the manufacturing process, regardless if they appear in the final drug product (e.g., solvents, nitrogen, silicon for stoppers, etc.). If the drug product is formulated using an active moiety, then the composition for the active ingredient should be clearly indicated (e.g., 1 mg of active ingredient base = 1.075 mg active ingredient hydrochloride). All overages should be clearly indicated (e.g., Contains 5 kg overage of the drug substance to compensate for manufacturing losses.). The components should be declared by their proper or common names, Quality standards (e.g., USP, Ph.Eur., House, etc.) and, if applicable, their grades (e.g., Microcrystalline Cellulose NF (PH 102)). P 3.3 Description of Manufacturing Process and Process Controls A flow diagram should be presented giving the steps of the process and showing where materials enter the process. The critical steps and points at which process controls, intermediate tests or final product controls are conducted should be identified. A narrative description of the manufacturing process, including packaging, that represents the sequence of steps undertaken and the scale of production should also be provided. Novel processes or technologies and packaging operations that directly affect product quality should be described with a greater level of detail. Equipment should, at least, be identified by type (e.g., tumble blender, in-line homogeniser) and working capacity, where relevant. Steps in the process should have the appropriate process parameters identified, such as time, temperature, or pH. Associated numeric values can be presented as an expected range. Numeric ranges for critical steps should be justified in Section P 3.4. In certain cases, environmental conditions (e.g., low humidity for an effervescent product) should be stated. Proposals for the reprocessing of materials should be justified. Any data to support this justification should be either referenced or filed in this section (P 3.3). The proposed commercial batch sizes should be stated. See section R 1 for discussion on production scale.
P 3.4 Controls of Critical Steps and Intermediates
1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443
Critical Steps: Tests and acceptance criteria should be provided (with justification, including experimental data) performed at the critical steps identified in P3.3 of the manufacturing process, to ensure that the process is controlled. Intermediates: Information on the quality and control of intermediates isolated during the process should be provided. Examples of applicable in-process controls include: (i) granulations: moisture, blend uniformity, bulk and tapped densities, particle size distribution; (ii)solid oral products: average weight, weight variation, hardness, thickness, friability, disintegration, weight gain during coating; (iii) semi-solids: viscosity, homogeneity, pH; (iv) transdermal patches: assay of drug-adhesive mixture, weight per area of coated patch without backing; (v) metered dose inhalers: fill weight/volume, leak testing, valve delivery; (vi) dry powder inhalers: assay of drug-excipient blend, moisture, weight variation of individually contained doses such as capsules or blisters; (vii) liquids: pH, specific gravity, clarity of solutions; (viii) parenterals: appearance, clarity, fill volume/weight, pH, filter integrity tests, particulate matter. Reference Guidances: Q2A, Q2B, Q6A P 3.5 Process Validation and/or Evaluation Description, documentation, and results of the validation and/or evaluation studies should be provided for critical steps or critical assays used in the manufacturing process (e.g., validation of the sterilisation process or aseptic processing or filling). Viral safety evaluation should be provided in A2, if necessary. The following information should be provided: (a) a copy of the process validation protocol, specific to this drug product, which identifies the critical equipment and process parameters that can affect the quality of the drug product and defines testing parameters, sampling plans, analytical procedures, and acceptance criteria; confirmation that three consecutive, production-scale batches of this drug product will be subjected to prospective validation in accordance with Health Canadas Validation Guidelines for Pharmaceutical Dosage Forms and Cleaning Validation Guidelines; if the process validation studies have already been conducted (e.g., as for sterile products), a copy of process validation report should be submitted in lieu of (a) and (b) above, a summary of these process validation studies should also be provided.
(b)
(c)
The manufacture of sterile drugs needs a well-controlled manufacturing area (e.g., a strictly controlled environment, highly reliable procedures, and numerous in-process controls). A detailed description of these conditions, procedures, and controls should be provided, together with actual copies of the following standard operating procedures: (a) washing, treatment, sterilizing, and depyrogenating of containers, closures, and equipment;
34
1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490
(b) (c) (d) (e) (f)
filtration of solutions; lyophilization process; leaker test of filled and sealed ampoules; final inspection of the product; and sterilization cycle.
The sterilization process used to destroy or remove microorganisms is probably the single most important process in the manufacture of parenteral drugs. The process can make use of moist heat (e.g., steam), dry heat, filtration, gaseous sterilization (e.g., ethylene oxide), or radiation. It should be noted that terminal steam sterilization, when practical, is considered to be the method of choice to ensure sterility of the final drug product. Therefore, scientific justification for selecting any other method of sterilization should be provided. The sterilization process should be described in detail, and evidence should be provided to confirm that it will produce a sterile product with a high degree of reliability and that the physical and chemical properties as well as the safety of the drug product will not be affected. Details such as Fo range, temperature range, and peak dwell time for a drug product and the container closure should be provided. Although standard autoclaving cycles of 121C, 15 minutes or more, would not need a detailed rationale; such justifications should be provided for reduced temperature cycles or elevated temperature cycles with shortened exposure times. If ethylene oxide is used, studies and acceptance criteria should control the levels of residual ethylene oxide and related compounds. Filters used should be validated with respect to pore size, compatibility with the product, absence of extractables and lack of adsorption of the drug substance or any of the components. Reference Guidances: Good Manufacturing Practices Validation Guidelines for Pharmaceutical Dosage Forms and Cleaning Validation Guidelines Validation Documentation Requirements and Responsibilities for Drug Fabricators, Packagers / Labellers, Distributors and Importers Sterilization Guidances: Aseptic Processes for Pharmaceuticals, Form-Fill-Seal for Pharmaceuticals, Gaseous Sterilization for Pharmaceuticals, Irradiation Sterilization for Pharmaceuticals, Moist Heat Sterilization for Pharmaceuticals P 4 Control of Excipients P 4.1 Specifications The specifications for excipients should be provided. This would include the specifications for all excipients, including those that do not appear in the final drug product (e.g., solvents, nitrogen, silicon for stoppers, etc.).
35
1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537
If the standard claimed for an excipient is a Schedule B compendial monograph, it is sufficient to state that the excipient is tested according to the requirements of that standard, rather than reproducing the specifications found in the Schedule B compendial monograph. If the standard claimed for an excipient is a non-Schedule B compendial monograph (e.g., House standard) or includes tests that are supplementary to those appearing in the Schedule B compendial monograph, a copy of the specification for the excipient should be provided. Testing for microbial requirements should be at least as stringent as those specified in the corresponding USP monograph should one exist (e.g., as for Magnesium Stearate). Excipients derived from natural sources should have appropriate microbial tests and limits. If additional purification is undertaken on commercially available excipients, details of the process of purification and modified specifications should be submitted. Reference Guidances: Q6A P 4.2 Analytical Procedures The analytical procedures used for testing the excipients should be provided, where appropriate. Copies of analytical procedures from Schedule B compendial monographs do not need to be submitted. Reference Guidances: Q2A Acceptable Methods P 4.3 Validation of Analytical Procedures Analytical validation information, including experimental data, for the analytical procedures used for testing the excipients should be provided, where appropriate. Copies of analytical validation information are normally not submitted for the testing of excipients. Reference Guidances: Q2A, Q2B Acceptable Methods P 4.4 Justification of Specifications Justification for the proposed excipient specifications should be provided, where appropriate. This would include the tests that are supplementary to those appearing in the Schedule B compendial monograph. Reference Guidances: Q3C
36
1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583
P 4.5 Excipients of Human or Animal Origin For excipients of human or animal origin, information should be provided regarding adventitious agents (e.g., sources, specifications, description of the testing performed, viral safety data). (Details in A2). This information should include biological source, country of origin, manufacturer, and a brief description of the suitability of use based on the proposed controls. For gelatin for use in pharmaceuticals, a letter of access from the proposed supplier should be provided to their Drug Master File, which is registered with Health Canada. Furthermore, confirmation should be included with a letter of attestation that the gelatin used is free of Bovine Spongiform Encephalopathy (BSE) / Transmissible Spongiform Encephalopathy (TSE). Reference Guidances: Q5A, Q5D, Q6B P 4.6 Novel Excipients For excipient(s) used for the first time in a drug product or by a new route of administration, full details of manufacture, characterisation, and controls, with cross references to supporting safety data (nonclinical and/or clinical) should be provided according to the drug substance and/or drug product format. (Details in A3). P 5 Control of Drug Product P 5.1 Specification(s) The specification(s) for the drug product should be provided. As defined in ICHs Q6A guidance document, a specification is a list of tests, references to analytical procedures, and appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for the tests described. It establishes the set of criteria to which a drug product should conform to be considered acceptable for its intended use. Conformance to specifications means that the drug product, when tested according to the listed analytical procedures, will meet the listed acceptance criteria. Specifications are critical quality standards that are proposed and justified by the manufacturer and approved by regulatory authorities as conditions of approval. A copy of the drug product specification(s) from the sponsor (as well from the company responsible for release testing, if different from the sponsor) should be provided, dated and signed by authorized personnel (i.e., the person in charge of the Quality Control department). The specification reference number, version, and date should be provided for version control purposes. The standard declared by the sponsor could be a
Draft date: 2001/07/18 37
1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616
Schedule B compendial standard (e.g., USP, BP, etc.), Manufacturers or House Standard, Prescribed Standard (e.g., Canadian Standard Drugs in Division C.06 of the Food and Drug Regulations), or a Professed Standard. Although a Schedule B compendial monograph may exist, a sponsor can choose to use a Manufacturers Standard which indicates that the material may differ in some respect from the compendial standard. However, according to section C.01.011 of the Food and Drug Regulations, no person shall use a manufacturers standard for a drug that provides (a) a lesser degree of purity than the highest degree of purity and (b) a greater variance in potency than the least variation in potency, provided for that drug in any publication mentioned in Schedule B to the Act. Therefore, if a manufacturers standard is used, the controls on purity (e.g., limits on specified degradation products) and potency should be as tight as the most stringent of those listed in the Schedule B compendial monographs. If the drug submission is for a non-official drug (e.g., where neither a Prescribed nor a Schedule B compendial standard exists), a professed standard is used and the product labelling for such products does not carry any standard. The specification can be summarized according to Health Canadas Quality Summary template including the Tests, Method Types, Sources, and Code Number/Version/Date. The acceptance criteria should also be provided in the summary of the specification(s). The Method Type should indicate the kind of analytical procedure used (e.g., visual, IR, UV, HPLC, etc.); the Source refers to the origin of the analytical procedure (e.g., USP, BP, House, etc.); and the Code Number/Version/Date should be provided for version control purposes. ICHs Q6A guidance document outlines recommendations for a number of universal and specific tests and criteria for drug products. The following information provides suggestions on specific tests and criteria that are not addressed by ICHs Q6A guidance document: Dosage Form Modified-release products Inhalation and Nasal Products Specific Tests a meaningful drug-release method consistency of delivered dose (throughout the use of the product), particle or droplet size distribution profiles (comparable to the product used in in vivo studies, where applicable), and if applicable for the dosage form, moisture content, leak rate, microbial limits, preservative assay, sterility, and weight loss uniformity of dosage units, melting point peal or shear force, mean weight per unit area, dissolution
1617 1618 1619 1620 1621 1622
Suppositories Transdermals
The test for uniformity of dosage units should be included in the specifications of all dosage forms where a variation in uniformity of dose from unit to unit can occur. The test for uniformity of dosage units could be physical (weight variation) or chemical (content uniformity), depending on the formulation, method of
Draft date: 2001/07/18 38
1623 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669
manufacture, and in-process testing. The requirements for testing the uniformity of dosage units have been developed by the Schedule B compendia, and it is recommended that these be used in order that an appropriate test be established. It is expected that the strictest compendial standard (e.g., for acceptance criteria) will be adopted. Reference Guidances: Q3B, Q3C, Q6A P 5.2 Analytical Procedures The analytical procedures used for testing the drug product should be provided. Copies of the House analytical procedures used during the drug development (if used to support testing results in the drug submission) as well as those proposed for routine testing should be provided. The tables in Health Canadas Quality Summary template can be used to summarize the analytical procedures. Unless modified, it is not necessary to provide copies of Schedule B compendial analytical procedures. The system suitability tests (SSTs) are an integral part of chromatographic analytical procedures. As a minimum, HPLC and GC methods should include SSTs for resolution and repeatability. For HPLC methods to control degradation products, this is typically done using a solution of the drug substance with a concentration corresponding to the limit for unspecified degradation products. Resolution of the two closest eluting peaks is generally recommended. However, choice of alternate peaks can be used if justified (e.g., choice of a toxic impurity). In accordance with the USP General Chapter on Chromatography and Health Canadas guidance document Acceptable Methods, the repeatability test should include an acceptable number of replicate injections (i.e., five or six). Reference Guidances: Q2A Acceptable Methods P 5.3 Validation of Analytical Procedures Analytical validation information, including experimental data, for the analytical procedures used for testing the drug product, should be provided. Copies of the validation reports for the analytical procedures used during the drug development (if used to support testing results in the drug submission) as well as those proposed for routine testing should be provided. The tables in Health Canadas Quality Summary template can be used to summarize the validation information. As outlined in Health Canadas guidance document Acceptable Methods, partial revalidation is necessary for methods that appear in a Schedule B compendial monograph. These revalidation criteria are recognized by other Regulatory Agencies and the compendia themselves. The compendial methods, as published, are typically validated using a drug substance or a drug product originating from a specific manufacturer. Different sources of the same drug substance or drug product can contain impurities and degradation products that were not considered during the development of the monograph.
39
1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716
If a Schedule B compendial standard is claimed and a House method is used in lieu of the compendial method (e.g., for potency or for specified degradation products), equivalency of the House and compendial methods should be demonstrated. This could be accomplished by performing duplicate analyses of one sample by both methods and providing the results from the study. Reference Guidances: Q2A, Q2B Acceptable Methods P 5.4 Batch Analyses A description of batches and results of batch analyses should be provided. This would include information such as strength, batch number, batch size, date and site of production, etc. on relevant drug product batches (e.g., used in nonclinical, clinical, comparative, stability, pilot, scale-up, and, if available, production-scale batches) used to establish the specification(s) and evaluate consistency in manufacturing. Analytical results tested by the company responsible for release testing should be provided from at least two batches of each strength. Bracketing and matrixing of proportional strengths can be applied, if scientifically justified. The testing results should include the batch(es) used in the nonclinical, clinical and/or comparative bioavailability studies. Copies of the certificates of analyses for these batches should be provided in the drug submission and the company responsible for generating the testing results should be identified. The individual results or the mean, the RSD, and the range for the content uniformity and dissolution tests should be included. The discussion of results should focus on observations noted for the various tests, rather than reporting comments such as All tests meet specifications. This should include ranges of analytical results and any trends that were observed. For quantitative tests (e.g., as in individual and total degradation product tests and potency tests), it should be ensured that actual numerical results are provided rather than vague statements such as within limits or conforms. A discussion and justification should be provided for any incomplete analyses (e.g., results not tested according to the proposed specification). If the proposed dosage form is a scored tablet, the results of a study should be provided testing the uniformity of dosage units of the manually-split tablet halves. The data provided in the drug submission should include a description of the test method, individual values, mean, and relative standard deviation (RSD). Uniformity testing (i.e., content uniformity or weight variation, depending on the dosage form) should be performed on each split portion from a minimum of 10 randomly selected whole tablets. As an illustrative example, the number of units (i.e., the splits) would be 20 halves for bisected tablets or 40 quarters for quadrisected tablets. At least one batch of each strength should be tested. Ideally, the study should cover a range of the hardness values. The splitting of the tablets should be performed in a manner that would be representative of that used by the consumer (i.e., manually split by hand). The uniformity test on split portions can be demonstrated on a one-time basis and does not need to be added to the drug product specification(s). The acceptance criteria (range and variation) should be as described in the USP General Chapter <905> Uniformity of Dosage Units for whole tablets. The tablet description on the drug product specifications, and under the Availability section of the Product Monograph, should reflect the presence of a score. Reference Guidances: Q3B, Q3C, Q6A
Draft date: 2001/07/18 40
1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763
P 5.5 Characterisation of Impurities Information on the characterisation of impurities should be provided, if not previously provided in S 3.2 Impurities. This information would include degradation products (e.g., from interaction of the drug substance with excipients or the container closure system), solvents in the manufacturing process for the drug product, etc.. The tables in Health Canadas Quality Summary template in section S 3.2 can be used to summarize this information. Reference Guidances: Q3B, Q3C, Q6A Identification, Qualification, and Control of Related Impurities in New Drugs Identification, Qualification, and Control of Related Impurities in Existing Drugs P 5.6 Justification of Specification(s) Justification for the proposed drug product specification(s) should be provided. This should include a discussion on the inclusion of certain tests, evolution of tests, analytical procedures, and acceptance criteria, differences from compendial standard, etc.. If the Schedule B compendial methods have been modified or replaced, a discussion should be included. The justification for certain tests, analytical procedures, and acceptance criteria may have been discussed in other sections of the drug submission (e.g., degradation products) and do not need to be repeated here, although a cross-reference to their location should be provided. The following sections outline considerations for the justification of specifications of some testing procedures and dosage forms. Other considerations are outlined in ICHs Q6A guidance document. In vitro Dissolution or Drug Release The results of studies justifying the choice of in vitro dissolution or drug release conditions (apparatus, rotation speed, medium) should be provided. Data should also be submitted to demonstrate whether the method is sensitive to changes in manufacturing processes and/or changes in grades and/or amounts of critical excipients. The dissolution method should be sensitive to any changes in the product that would result in a change in one or more of the pharmacokinetic parameters. Use of single point test or a dissolution range should be justified based on the solubility and/or biopharmaceutical classification of the drug. Modified-release dosage forms should have a meaningful in vitro release rate (dissolution) test that is used for routine quality control. Preferably this test should possess in vitro-in vivo correlation. Results demonstrating the effect of pH on the dissolution profile should be submitted if appropriate for the type of dosage form. The testing conditions should be set to cover the entire time period of expected release (e.g., at least three
Draft date: 2001/07/18 41
1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810
test intervals chosen for a 12-hour release and additional test intervals for longer duration of release). One of the test points should be at the early stage of drug release (e.g., within the first hour) to demonstrate absence of dose dumping. At each test period, upper and lower limits should be set for individual units. Generally, the acceptance range at each intermediate test point should not exceed 25% or 12.5% of the targeted value. Dissolution results should be submitted for several lots, including those lots used for pharmacokinetic and bioavailability studies. Transdermals Adhesion of the patch should be tested to evaluate the patchs adhesive property (also termed a peel test or shear test). It is a numerical value obtained from an in vitro test and is useful to detect any manufacturing anomaly and serves as an index to monitor stability. The results of studies justifying the choice of dissolution conditions (apparatus, rotation speed, medium) should be provided. Data should also be submitted to demonstrate whether the drug release method is sensitive to changes in manufacturing processes and/or changes in grades and/or amounts of critical excipients. The dissolution method should be sensitive to any changes in the product that would result in a change in one or more of the pharmacokinetic parameters. P 6 Reference Standards or Materials Information on the reference standards or reference materials used for testing of the drug product should be provided, if not previously provided in S 5 Reference Standards or Materials. See section S 5 for information that should be provided on reference standards or materials. Reference Guidances: Q6A Acceptable Methods P 7 Container Closure System A description of the container closure systems should be provided, including the identity of materials of construction of each primary packaging component and its specification. The specifications should include description and identification (and critical dimensions, with drawings where appropriate). Non-compendial methods (with validation) should be included, where appropriate. For non-functional secondary packaging components (e.g., those that neither provide additional protection nor serve to deliver the product), only a brief description should be provided. For functional secondary packaging components, additional information should be provided. Suitability information should be located in P 2. Provide a description and specifications for the packaging components that:
42
1811 1812 1813 1814 1815 1816 1817 1818 1819 1820 1821 1822 1823 1824 1825 1826 1827
(a) (b) (c) (d)
come in direct contact with the dosage form (container, closure, liner, desiccant); are used as a protective barrier to help ensure stability or sterility; are used for drug delivery; are necessary to ensure drug product quality during transportation;
Include all proposed market containers as well as sample packs for physicians. The tables in Health Canadas Quality Summary template can be used to summarize the above information. The information for the container closure system depends on the dosage form and route of administration. The following table outlines the general recommendations for the various dosage forms (some of this highlighted information can be performed on a one-time basis to establish the suitability of the container closure system and should be discussed in section P 2): Solid Oral Products Specifications for routine testing: - Name, physical description, dimensions (e.g., thickness, etc.) - Specific identification tests (e.g., IR) for components that come in direct contact with the dosage form Qualification of components: - Composition and drawings for all components (including cap liners, coatings for metal tubes, elastomers, adhesives, silicon, etc.) - Description of any additional treatments* - USP <661> Containers - USP <671> Containers - Permeation - USP <381> Elastomeric Closures for Injections * x x x x x x x x x x Oral Liquid and Topical Products Sterile Products (including Ophthalmics)
1828 1829 1830 1831 1832 1833 1834 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847
x (sterilization and depyrogenation of the components) x (includes USP <87> / <88> tests) x x (includes USP <87> / <88> tests)
x x --
x x --
e.g., coating of tubes, siliconization of rubber stoppers, sulphur treatment of ampoules/vials information should be submitted
43
1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 1862 1863 1864 1865 1866 1867 1868 1869 1870 1871 1872 1873 1874 1875 1876 1877 1878 1879 1880 1881 1882 1883 1884 1885 1886 1887 1888 1889 1890 1891 1892
--
information does not need to be submitted
Comparative studies can be necessary for changes in components (e.g., comparative delivery study (droplet size) for a change in supplier of dropper tips). The information on the composition should be available to Health Canada either in the drug submission or in a Drug Master File. Refer to Health Canada's guidance document Product Master Files (soon to be renamed Drug Master Files) for filing requirements for Type II DMF's (packaging materials). P 8 Stability As outlined in ICHs Q1A guidance document, the purpose of stability testing is to provide evidence on how the quality of a drug product varies with time under the influence of a variety of environmental factors such as temperature, humidity, and light, and to establish a shelf life for the drug product and recommended storage conditions. Reference Guidances: Q1A, Q1B, Q1C Stability Testing of Existing Drug Substances and Products
P 8.1 Stability Summary and Conclusions The types of studies conducted, protocols used, and the results of the studies should be summarised. The summary should include, for example, conclusions with respect to storage conditions and shelf life, and, if applicable, in-use storage conditions and shelf life. Stress testing: As outlined in ICHs Q1A guidance document, photostability testing should be conducted on at least one primary batch of the drug product if appropriate. Stress testing of other types of dosage forms may be appropriate (e.g., cyclic studies of semi-solids, freeze-thaw studies). Accelerated and long term testing: The conditions for stability testing of drug products are outlined in ICHs Q1A guidance document. The following storage conditions and minimum data at the time of submission are recommended by ICHs Q1A guidance document for the Primary Batches. When significant change occurs at any time during 6 months testing at the accelerated storage condition, additional testing at the intermediate storage condition should be conducted and evaluated against significant change criteria. The initial application should include a minimum of 6 months data from a 12-month study at the intermediate storage condition. See ICHs Q1A guidance document for definition of significant change.
44
1893 1894 1895 1896 1897 1898 1899 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1910 1911 1912 1913 1914 1915 1916 1917 1918 1919 1920 1921 1922 1923 1924 1925 1926 1927 1928 1929 1930 1931 1932 1933 1934 1935 1936
Study Long term Intermediate Accelerated
Storage Condition 25C 2C / 60% RH 5% RH 30C 2C / 60% RH 5% RH 40C 2C / 75% RH 5% RH
Minimum Time Period Covered by Data at Submission 12 months 6 months 6 months
RH = relative humidity Other conditions are outlined in the ICHs Q1A guidance document for drug products intended for storage in a refrigerator and those intended for storage in a freezer. Drug products intended for storage below -20C should be treated on a case-by-case basis. For existing drugs (e.g., generics), stability information from accelerated and long term testing should be provided on at least two batches of each strength in the container closure system proposed for marketing. Bracketing and matrixing can be applied, if scientifically justified. See Health Canadas guidance document Stability Testing of Existing Drug Substances and Products for further details. For sterile products, sterility should be reported at the beginning and end of shelf life. For parenteral products, sub-visible particulate matter should be reported frequently, but not necessarily at every test interval. Bacterial endotoxins need only be reported at the initial test interval. Weight loss from plastic containers should be reported over the shelf life. In-use periods beyond 28 days for parenteral and ophthalmic products should be justified with experimental data.
The information on the stability studies should include details such as storage conditions, strength, batch number, batch size, container closure system, and completed (and proposed) test intervals. The discussion of results should focus on observations noted for the various tests, rather than reporting comments such as All tests meet specifications. This should include ranges of analytical results and any trends that were observed. For quantitative tests (e.g., as in individual and total degradation product tests and potency tests), it should be ensured that actual numerical results are provided rather than vague statements such as within limits or conforms. Proposed storage conditions and shelf life: The proposed storage conditions with suitable tolerances (e.g., a temperature range with upper and lower criteria) and shelf life for the drug product should be provided. When the drug product has been shown to be stable (e.g., under the ICH conditions with long term studies at 25EC 2EC/60% RH 5% RH and accelerated studies at 40EC 2EC/75% RH 5% RH), the following storage recommendation would generally be considered acceptable: "Store at controlled room temperature (15EC to 30EC)." Based on the results of the stability evaluation, other storage precautions may be warranted (e.g., "Protect from light", "Protect from moisture").
Draft date: 2001/07/18 45
1937 1938 1939 1940 1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983
Limited extrapolation of the real time data from the long term storage condition beyond the observed range to extend the shelf life can be undertaken at approval time, if justified. P 8.2 Post-approval Stability Protocol and Stability Commitment The post-approval stability protocol and stability commitment should be provided. When available long term stability data on primary batches do not cover the proposed shelf life granted at the time of approval, a commitment should be made to continue the stability studies post-approval in order to firmly establish the shelf life. The long term stability studies for the Commitment Batches should be conducted through the proposed shelf life (and the accelerated studies for six months) on at least three production batches of each strength (or two production batches of each strength for existing drugs). A Continuing Stability Programme is implemented to ensure compliance with the approved shelf life specifications. A minimum of one batch of every strength of the drug product is enrolled into the continuing stability programme each year. The stability protocols for the Commitment Batches and Continuing (i.e., ongoing) Batches should include, but not limited to: (a) (b) (c) (d) (e) Number of batches per strength and batch sizes; Tests and acceptance criteria; Container closure system(s); Testing frequency; and Storage conditions (and tolerances) of samples
Any differences in the stability protocols used for the primary batches and those proposed for the Commitment Batches or Continuing Batches should be scientifically justified. P 8.3 Stability Data Results of the stability studies should be presented in an appropriate format (e.g. tabular, graphical, narrative). Information on the analytical procedures used to generate the data and validation of these procedures should be included. Information on characterisation of impurities is located in P 5.5. The actual stability results (i.e., raw data) used to support the proposed shelf life should be provided in the drug submission. For quantitative tests (e.g., as in individual and total degradation product tests and potency tests), it should be ensured that actual numerical results are provided rather than vague statements such as
Draft date: 2001/07/18 46
1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
within limits or conforms. A APPENDICES A 1 Facilities and Equipment Not applicable (i.e., not a Biotech product). A 2 Adventitious Agents Safety Evaluation For excipients of human or animal origin, information should be provided regarding adventitious agents (e.g., sources, specifications, description of the testing performed, viral safety data). A 3 Novel Excipients For excipient(s) used for the first time in a drug product or by a new route of administration, full details of manufacture, characterisation, and controls, with cross references to supporting safety data (nonclinical and/or clinical) should be provided according to the drug substance and/or drug product format.
R REGIONAL INFORMATION R 1 Production Documentation R 1.1 Executed Production Documents A minimum of two batches of each strength should be manufactured. Bracketing and matrixing of proportional strengths can be applied, if scientifically justified. These batches should be manufactured by a procedure fully representative of and simulating that to be applied to a full production scale batch. For solid oral dosage forms, a pilot scale is generally, at a minimum, one-tenth that of a full production scale or 100,000 tablets or capsules, whichever is the larger. Copies of the executed production documents should be provided for the batches used in the pivotal clinical and/or comparative bioavailability studies. Any notations made by operators on the executed production documents should be clearly legible.
47
2029 2030 2031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 2043 2044 2045 2046 2047 2048 2049 2050 2051 2052 2053 2054 2055 2056 2057 2058 2059 2060 2061 2062 2063 2064 2065 2066 2067 2068 2069 2070 2071 2072 2073 2074 2075
According to the Food and Drugs Act: A device means any article, instrument, apparatus or contrivance, including any component, part or
Draft date: 2001/07/18 48
R 1.2 Master Production Documents Copies of the drug product master production documents should be provided for each proposed strength, commercial batch size, and manufacturing site. The details in the master production documents should include, but not limited to, the following: (a) (b) dispensing, processing and packaging sections with relevant material and operational details; relevant calculations (e.g., if the amount of drug substance is adjusted based on the potency results or on the anhydrous basis, etc.); identification of all equipment by type and working capacity; process parameters (e.g., mixing time, mixing speed, milling screen size, processing temperature range, tablet machine speed, etc.); list of in-process tests (e.g., appearance, pH, potency, blend uniformity, viscosity, particle size distribution, LOD, weight variation, hardness, disintegration time, weight gain during coating, leaker test, minimum fill, clarity); sampling plan with regard to the: (i) (ii) (iii) steps where sampling should be done (e.g., drying, lubrication, compression) number of samples that should be tested (e.g., blend drawn using a sampling thief from x number of different parts of the blender) frequency of testing (e.g., weight variation every x minutes during compression or capsule filling);
(c) (d)
(e)
(f)
(g)
precautions necessary to ensure product quality (e.g., temperature and humidity control, maximum holding times); theoretical and actual yield; compliance with the Good Manufacturing Practices (GMP) requirements as per the provisions of Division C.02 of the Food and Drug Regulations.
(h) (i)
Reference Guidances: Good Manufacturing Practices R 2 Medical Devices
2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 2117 2118 2119
accessory thereof, manufactured, sold or represented for use in: (a) the diagnosis, treatment, mitigation or prevention of a disease, disorder or abnormal physical state, or its symptoms, in human beings or animals, restoring, correcting or modifying a body function or the body structure of human beings or animals, the diagnosis of pregnancy in human beings or animals, or the care of human beings or animals during pregnancy and at and after birth of the offspring, including care of the offspring,
(b)
(c) (d)
and includes a contraceptive device but does not include a drug. A drug includes any substance or mixture of substances manufactured, sold or represented for use in (a) the diagnosis, treatment, mitigation or prevention of a disease, disorder, abnormal physical state, or its symptoms, in human beings or animals, restoring, correcting or modifying organic functions in human beings or animals, or disinfection in premises in which food is manufactured, prepared or kept.
(b) (c)
Combination products will be classified as either medical devices or drugs according to the principal mechanism of action by which the claimed effect to purpose is achieved. Those combination products that have been classified as devices include drug coated devices such as catheters, pacemaker leads, drug impregnated devices. Those that have been classified as drugs include prefilled syringes, transdermal patches, peritoneal dialysis solutions, implants whose primary purpose is to release a drug. A description and details on medical devices used to deliver the dosage form that are external to the drug product (e.g., eye droppers, plastic applicators, etc.) should be provided. M MISCELLANEOUS M 1 ICH Quality Guidance Documents (Chemical Entities)
ICH Quality Guidances Documents (date adopted by Health Canada) Q1A/R - Stability Testing of New Drug Substances and Products Q1B - Stability Testing: Photostability Testing of New Drug Substances and Products (1999) Q1C - Stability Testing: Requirements for New Dosage Forms (1998)
Access
<not yet adopted>* TPD Website
TPD Website
49
2120 2121 2122 2123 2124 2125 2126 2127 2128 2129 2130 2131 2132
Q2A - Text on Validation of Analytical Procedures (1999) Q2B - Validation of Analytical Procedures: Methodology (1999) Q3A - Impurities in New Drug Substances (1995) Q3B - Impurities in New Drug Products (1999) Q3C - Impurities: Guideline for Residual Solvents (1999) Q6A - Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Products: Chemical Substances and Products Q7A - Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients M4Q - Common Technical Document - Quality
TPD Website TPD Website Guidelines Order Form TPD Website TPD Website <not yet adopted>*
<not yet adopted>* <not yet adopted>*
* Available on ICHs Website: www.ifpma.org/ich1.html
50
2133 2134 2135 2136 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 2158 2159 2160 2161 2162 2163 2164 2165 2166 2167 2168 2169 2170
Guidelines Order Form: Guidelines listed on the Guidelines Order Form are available in printed form only, through the Canadian Government Publishing Centre (CGPC). The Order Form is available on the TPD Website under Forms or from the CGPC (Tel: (819) 956-4800; Fax: (819) 994-1498; Internet: http://publications.pwgsc.gc.ca). Health Canadas Therapeutic Products Directorate (TPD) website: www.hc-sc.gc.ca/hpb-dgps/therapeut Health Canada Quality Templates Quality Overall Summary - Chemical Entities (New Drug Submissions or Abbreviated New Drug Submissions) (QOS-CE (NDS)) (DRAFT, 2001) Analytical Procedures and Validation Information Summaries (DRAFT, 2001) Certified Product Information Document - Chemical Entities (CPID-CE) (DRAFT, 2001) Access TPD Website
M 2 Health Canada Quality Templates and Guidance Documents (Chemical Entities)
TPD Website TPD Website
Health Canada Quality Guidance Documents Acceptable Methods (1994) Chemistry and Manufacturing: New Drugs (1990) Extension of Expiration Dates (1992) Identification, Qualification, and Control of Related Impurities in New Drugs (DRAFT, 1999) Identification, Qualification, and Control of Related Impurities in Existing Drugs (DRAFT, 1999) Marketed New Drug Products, Changes to (1994) Marketed New Drug Products, Stability Requirements for Changes to (1994) Product Master Files (soon to be renamed Drug Master Files) (1994) Quality (Chemistry and Manufacturing) Guidance: New Drug Submissions (NDSs) and Abbreviated New Drug Submissions (ANDSs) (DRAFT, 2001) Reduction in the Use of Dichloromethane in Tablet Coating Operations (DRAFT, 1997) Stability Testing of Existing Drug Substances and Products (DRAFT, 1997) Stereochemical Issues in Chiral Drug Development (2000)
Access Guidelines Order Form Guidelines Order Form TPD Website TPD Website
TPD Website
TPD Website TPD Website Guidelines Order Form TPD Website
TPD Website
TPD Website TPD Website
51

Health Canada Quality Guidance

Uploaded by

Copyright:

Available Formats

Health Canada Quality Guidance

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Health Canada Quality Guidance

Uploaded by

Copyright:

Available Formats

DRAFT GUIDANCE FOR INDUSTRY Quality (Chemistry and Manufacturing) Guidance: New Drug Submissions (NDSs) and Abbreviated

New Drug Submissions (ANDSs)

Published by authority of the Minister of Health

Health Products and Food Branch Guidance Document

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Draft date: 2001/07/18

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Draft date: 2001/07/18

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Draft date: 2001/07/18

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Draft date: 2001/07/18

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Draft date: 2001/07/18

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Draft date: 2001/07/18

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Draft date: 2001/07/18

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Draft date: 2001/07/18

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Particle size distribution:

Draft date: 2001/07/18

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Draft date: 2001/07/18

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Draft date: 2001/07/18

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Draft date: 2001/07/18

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs

Draft date: 2001/07/18

Health Canada Draft Guidance for Industry

Quality (Chemistry and Manufacturing) Guidance: NDSs and ANDSs